For cancers, including CRC, inhibition of TNFR2 or depletion of TNFR2-expressing cells can be achieved with the conventional antibody technology, and both in vitro and in vitro observations have been encouraging [44,57,89,94]. The gene discussed is TNFRSF1B; the disease is colorectal carcinoma.